Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9217667 | 0.78 | MAPT (0.47) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL9226507 | 0.76 | MAPT (0.45) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL10523358 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL9712158 | 0.74 | MAPT (0.48) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL2007179 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL25284860 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL3614652 | 0.74 | MAPT (0.48) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL6833296 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL852172 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL18084487 | 0.74 | MGAM (0.44) | MAPTESR1ESR2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2003-07-24 | — | — | US | disclosed |
| US-6548673-B1 | Alkylation using transition metal complex catalyst; purified by acid/base extraction | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-6531602-B2 | Desilylation of a 2-pyridylsilane to form an alcohol | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2002-11-07 | — | — | US | disclosed |
| EP-1035125-A2 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | H1-0, RIOK2, H1-4 | MAPT 4595/4885ESR1 4502/4885ESR2 3867/4885 |
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | H1-0, H1-4, H1-2 | MAPT 4583/4885ESR1 4521/4885ESR2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.